SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rebound is being linked by traders to Morgan Stanley naming it a top pick on AWS growth and AI prospects, as well as AWS making its Trainium chips easier for developers to use. Bulls welcome the move and point to cloud and AI momentum, while skeptics question whether it can hold amid heavy capex and recent volatility.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, strengthening the case for an FDA resubmission, though approval is still pending. Traders are debating the significance of dizziness reported among treated patients and speculating about a short squeeze amid volatile trading.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported takeover interest from Lundbeck is driving speculation about a potential bid or bidding war and heightened trading activity. Xeris has said it is not for sale, leaving traders divided between treating the chatter as a credible deal catalyst and focusing on Recorlev growth and XP-8121s pipeline prospects.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention ahead of its Q3 report after raising its outlook twice, with traders citing higher royalties from its AI-focused Vertical Power Delivery licensing. Bulls see the pullback as a buying opportunity and expect strong results, while others point to the stocks volatility and selling despite the improved outlook.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-expected third quarter and an upbeat 2027 EBITDA outlook are driving CLFs rally, with bullish traders anticipating short covering. Others warn the outlook depends on steel prices and remain focused on the companys debt, while some see the move as a sell-the-news bounce.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders citing insider share sales and upcoming lockup releases as added supply pressure alongside concerns about valuation, growth and its OpenAI exposure. Bears warn of further downside, while bulls argue the decline is overdone and are buying the dip; some also attribute weakness to a broader AI and semiconductor-sector retreat.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-cleared expansion of Alpha Taus REGAIN trial in recurrent glioblastoma is a key focus, alongside planned trial data at SNO 2026. Traders are optimistic about early local-control results, while some note that they come from a small initial cohort; the completed enrollment of the pancreatic IMPACT study is another pipeline catalyst discussed.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is drawing attention amid a persistent selloff and weak solar-sector sentiment, with traders pointing to interest-rate sensitivity, policy and financing concerns, and analyst target cuts. The debate is whether its AI data-center, battery-storage and virtual-power-plant initiativesand perceived high short interestcould offset those pressures; some traders view them as a potential turnaround catalyst, while others remain bearish.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios FDA expansion of Anktiva plus BCG to papillary-only bladder cancer, alongside positive long-term trial data, is the main focus. The share-price decline despite those developments has prompted debate over profit-taking, broader biotech weakness and options activity, while some traders allege manipulation without substantiation.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

RGCs sharp move higher is drawing momentum-trading interest, with traders speculating about a repeat meme-stock or short-squeeze run based on its past spikes and reportedly tight share float. Others warn the move may be a pump-and-dump, citing the companys weak fundamentals and the stocks extreme volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks Investment Ideas feature highlights: Alibaba, Baidu, Kingsoft Cloud, Tencent, Hesai, Pony AI and WeRide

BABA, BIDU, KC, TCEHY and HSAI highlight China's expanding AI ecosystem, while PONY and WRD add autonomous-driving exposure.

Trump-Xi Meeting Puts These 5 Chinese AI Stocks in Focus

As China's AI ecosystem continues to expand, these stocks provide investors with several different ways to monitor the country's accelerating AI buildout.

Sprout Social (SPT) Surges 14.0%: Is This an Indication of Further Gains?

Sprout Social (SPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Is Tencent (TCEHY) a Solid Growth Stock? 3 Reasons to Think "Yes"

Tencent (TCEHY) could produce exceptional returns because of its solid growth attributes.

Top China Tech Plays in US Markets Amid Trade Deal Progress

Kingsoft Cloud and peers gain appeal as U.S.-China trade easing and policy shifts lift confidence in Chinese tech into 2026.

TCEHY Stock Declines 4% as Q1 Earnings and Revenues Miss Estimates

Tencent shares slide after Q1 misses, though AI-led ad growth, gaming gains and rising cloud demand support revenue growth.

NVDA Stock Jumps Premarket: US Reportedly Clears H200 Chip Sales To 10 China Firms

Equity

The U.S. Commerce Department has cleared Nvidia server sales to Alibaba, Tencent, JD.com, and ByteDance, among others, according to a Reuters report.


April PPI Touches Highest Level Since March 2022

April PPI Touches Highest Level Since March 2022.

PPI Sees Wholesale Inflation Shoot Up to +6.0%

Headline PPI month over month pole-vaulted to +1.4%, nearly 3x the +0.5% anticipated.

Tencent Q4 Earnings Beat Estimates, Revenues Increase Y/Y

TCEHY beat Q4 earnings as revenues rise 13% y/y, driven by gaming and marketing services, along with margin expansion despite higher expenses.

Tencent Holdings Ltd. engages in the development and operation of digital platforms and provides fintech and cloud services. It operates through the following segments: Value-Added Services, FinTech and Business Services, Marketing Services, and Others. The Value-Added Services segment is involved in online and mobile games, community value-added services, and applications across various Internet and mobile platforms. The FinTech and Business Services segment offers fintech and cloud services, which include commissions from payment, wealth management and other services. The Marketing Services segment provides performance-based and display advertising. The Others segment includes financial results from investments, as well as activities such as film and television production and distribution for third parties, copyright licensing, merchandise sales, and other related operations The company was founded by Yi Dan Chen, Hua Teng Ma, Chen Ye Xu, Li Qing Zeng, and Zhi Dong Zhang on November 11, 1998, and is headquartered in Shenzhen, China.

Tencent Holdings Ltd. - ADR

Bullish Sentiment

<ul class="summary-bullets"><li>Nvidia CEO Jensen Huang is in China as part of a delegation led by U.S. President Donald Trump.</li><li>The two-day summit is expected to address issues including trade, the Iran war, and Taiwan.</li><li>Stocktwits sentiment for NVDA remained ‘extremely bullish.’</li></ul>Nvidia shares inched over 2% higher in early premarket trading on Thursday, extending their rally, as investors tuned into news from China, where U.S. President Donald Trump and top tech executives, including the chipmaker’s CEO Jensen Huang, are holding bilateral talks with Chinese leadership.Chatter on Stocktwits indicated that retail investors see Huang’s last-minute&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvda-rallies-as-ceo-jensen-huang-arrives-in-china-traders-eye-china-sales-revival-ahead-of-earnings/cZX1hvIRe1R">entry</a> as a potentially crucial catalyst for the company, particularly if it helps secure a breakthrough in the trade deadlock that has blocked Nvidia server sales to Chinese customers.With meetings underway in Beijing, Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/retail-consumer/us-clears-h200-chip-sales-10-china-firms-nvidia-ceo-looks-breakthrough-2026-05-14/">reported</a>, citing its sources, that the U.S. Commerce Department has approved the sale of Nvidia’s H200 to as many as 10 Chinese firms. The list includes Alibaba, Tencent, ByteDance, and&nbsp;JD.com.Alibaba’s U.S.-listed shares declined 3.4% in the premarket session, while JD’s stock fell nearly 2%A handful of distributors, including Lenovo and Foxconn, have also been approved, according to the report. Buyers can purchase either directly from Nvidia or through intermediaries, and each approved customer can purchase up to 75,000 chips under the U.S. licensing terms, according to Reuters.Meanwhile, Huang told ​state broadcaster CCTV ‌on Thursday that he hoped ​Trump and his Chinese ​counterpart Xi Jinping would ⁠build on their ​good relationship during talks ​in Beijing to improve two-way ties.<h2 class="st-heading-2">Retail View On NVDA</h2>On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/NVDA">NVDA</a> held firmly in the ‘extremely bullish zone, unchanged since last week, with several traders expecting the stock to rally ahead of Nvidia’s quarterly report next week.“$NVDA going up on china speculation is crazy…this is a $250 stock minimum with no china revenue,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.stocktwits.com/Notsad21/message/653314891">said</a> a trader.<h2 class="st-heading-2">NVDA’s China Pressures</h2>Investor sentiment and gains across semiconductor stocks have surged to record highs lately. Until recently, Nvidia, the sector’s standout player, has curiously lagged behind. Among other factors, the erosion in the company’s business in China due to U.S. export restrictions has been a key overhang.Huang recently said Nvidia’s revenue from China has effectively dropped to zero, reiterating the detail from the company’s latest results. Just two years ago, Nvidia was a dominant chip supplier in the region, accounting for $25 billion in market sales, or 32% of the company’s total revenue in 2024.Nvidia shares gained 14% in April. In comparison, the iShares Semiconductor ETF (SOXX) rallied 40.4%, recording its best month on record.However, NVDA has picked up steam lately. As of Wednesday, the stock had risen for six straight sessions, for a total of 15%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nvidia CEO Jensen Huang waves as he prepares to depart following a welcome ceremony at the Great Hall of the People on May 14, 2026 in Beijing, China. (Photo by Alex Wong/Getty Images)

The U.S. Commerce Department has cleared Nvidia server sales to Alibaba, Tencent, JD.com, and ByteDance, among others, according to a Reuters report.

Alibaba Group Holding Ltd

JD.com Inc - ADR

Bullish

Bearish

Neutral

Show me the results

What's your take on Alibaba ($BABA) stock right now - bullish, bearish, or neutral? Vote in the poll and share your outlook in the comments then check back to see what others think.

Are you bullish, bearish, or neutral on Alibaba ($BABA) stock right now?

Stocktwits

Are you bullish, bearish, or neutral on Alibaba (

Current Price	$52.59
Prev Close	$52.75
Open	$53.40
Dividend Yield	0.79%
50-Day Moving Average	$55.73
Beta	0.69
Avg. Volume	3.26M
PE Ratio	14.18

52-Week High	$86.00
52-Week Low	$52.40
Market Capitalization	$475.19B
EPS (Annual)	$3.44
Price to Book	2.84
Revenue Per Employee	$902,724.55

Feed

News

Sentiment

Earnings

Fundamentals

Info

TCEHY Fundamentals